$5.5 Billion Worldwide Surgical Site Infection Control Industry to 2027 - Featuring 3M, Ansell, Covalon Technologies and GAMA Healthcare Among Others

News provided by

Jul 11, 2022, 14:15 ET

DUBLIN, July 11, 2022 /PRNewswire/ -- The "Surgical Site Infection Control Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global surgical site infection control market reached a value of US$ 4.20 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 5.51 Billion by 2027, exhibiting a CAGR of 4.63% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Surgical site infection (SSI) control refers to various practices or measures employed to prevent infections among patients during their stay at the hospital. These infections occur after surgery in the operated part of the body, leading to poor wound healing and extended overnight stays for the treatment. SSI control is essential as these infections can be severe and affect tissues, organs, or implants.

Some commonly used SSI control products include surgical drapes, gloves, hair covers, disinfectants, skin preparation solutions, scrubs, and medical nonwovens. In recent years, SSI control solutions have gained traction across the healthcare sector as they help prevent infections, enhance patient care quality, and improve surgical outcomes and success rates.

SSI control products assist in reducing the duration of hospital stays, eliminating the need for revision surgeries, and minimizing patient discomfort. As a result, the rising cases of hospital-acquired infections represent the primary factor driving the market growth. Besides this, the growing awareness regarding SSIs and the shifting focus toward infection prevention through proper control measures are augmenting the product demand.

Additionally, there has been a significant increase in the prevalence of chronic conditions, such as cancer, gastrointestinal disorders, and cardiovascular diseases (CVDs), due to the aging population, sedentary lifestyles, and unhealthy eating habits. This, in confluence with the increasing number of patients undergoing surgical procedures, is accelerating the adoption of SSI control products.

Furthermore, several favorable initiatives undertaken by the governing and non-governing agencies of various countries, such as the introduction of stringent guidelines and training programs focused on infection control practices, are catalyzing the market growth. Moreover, the rising integration of SSI control products with advanced technologies, improving healthcare infrastructure, and ongoing research and development (R&D) activities are some of the factors creating a positive market outlook.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Ansell Limited, Becton Dickinson and Company, bioMerieux SA. (Institut Merieux), Covalon Technologies Ltd., GAMA Healthcare Ltd., Getinge AB (Carl Bennet AB), Johnson & Johnson, Kimberly-Clark Corporation, Molnlycke Health Care AB, Prescient Surgical, Steris Corporation.

Key Questions Answered in This Report:

How has the global surgical site infection control market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global surgical site infection control market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the infection type?
What is the breakup of the market based on the surgery type?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global surgical site infection control market and who are the key players?
What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Surgical Site Infection Control Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product
6.1 Antibiotic Prophylaxis Products
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Wound Care Dressings
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Surgical Drapes
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Surgical Clippers
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Antiseptics and Disinfectants
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Wound Irrigation Products
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast

7 Market Breakup by Infection Type
7.1 Superficial Incisional SSI
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Deep Incisional SSI
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Organ or Space SSI
7.3.1 Market Trends
7.3.2 Market Forecast

8 Market Breakup by Surgery Type
8.1 Cesarean Section
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Gastric Bypass
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Cataract Surgery
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Dental Restoration
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast

9 Market Breakup by End User
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Ambulatory Surgical Centers
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 3M Company
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Ansell Limited
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Becton Dickinson and Company
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 bioMerieux SA. (Institut Merieux)
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Covalon Technologies Ltd.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 GAMA Healthcare Ltd.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.7 Getinge AB (Carl Bennet AB)
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Johnson & Johnson
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Kimberly-Clark Corporation
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Molnlycke Health Care AB
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 SWOT Analysis
15.3.11 Prescient Surgical
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.12 Steris Corporation
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio

For more information about this report visit https://www.researchandmarkets.com/r/6ccy93